Desmopressin: Medicine Overview
Desmopressin is a lab-made version of the hormone vasopressin. See its US label uses, what trials show for bedwetting and night-time urination, and the sodium risk.
Content last updated . This page has not been medically reviewed.
What it is
Desmopressin acetate is a synthetic analogue (a lab-made, modified copy) of the natural pituitary hormone arginine vasopressin, also called antidiuretic hormone, or ADH. [1] It is a prescription medicine, not a supplement. "DDAVP" is one brand name, "desmopressin" is the active ingredient, and tablets, injection and nasal spray are different formulations with different labels. See why brand, ingredient, formulation and indication are not interchangeable.The antidiuretic effect comes from stimulating vasopressin 2 (V2) receptors in the kidney, which increases water re-absorption and reduces urine production. [2] Compared with vasopressin, the change in structure gave a longer duration of action and less effect on blood vessels. [2]
What the research shows
Bedwetting in children (approved use for tablets). A 2025 Cochrane review included 95 studies with 8,473 participants, of whom 5,434 received desmopressin. [4] The review rated the evidence quality as low or very low overall. [4] Against placebo, desmopressin may reduce wet nights per week (mean difference -1.81), and probably leads to more children reaching 14 consecutive dry nights (risk ratio 3.18, moderate certainty). [4] Side effects may differ little from placebo, though that finding is low certainty. [4] Against alarm training, the difference in wet nights was uncertain. [4] Label: approved medicine; trial evidence mixed in certainty.Night-time urination in adults. A meta-analysis in men with benign prostatic hyperplasia (four articles, 500 patients) found less nocturia with oral desmopressin, but more short-term adverse events: headache 20%, dizziness 5.88%, nausea 4.71% and hyponatremia 4.71%. [5] A review of people with neurological disease (14 studies, 200 patients, mostly intranasal) pooled three trials and found about 0.75 fewer night-time urinations than placebo, from low or medium quality trials. [6] Label: promising but limited.
Questions this page does not answer
It gives no dose, schedule or advice to start, stop or switch. Non-label uses, and any desmopressin product sold outside regulated pharmacies, were not evaluated. Talk with the prescriber about any change.Related guides
- Oxytocin: hormone and medicine, a related pituitary peptide whose label also warns about water intoxication.
- Endocrine and reproductive peptide medicines
- Hormones vs peptides
Frequently asked questions
Is desmopressin the same as vasopressin?
No. Desmopressin is a synthetic analogue of vasopressin with a longer action and less effect on blood vessels. [1][2]
Is desmopressin approved for bedwetting?
In the US, DDAVP tablets are approved for primary nocturnal enuresis. [1] Trial evidence shows more dry nights than placebo, though overall quality was rated low or very low. [4]
Is desmopressin approved for waking at night to urinate?
This was not verified. The US labels read do not list nocturia, although trials in adults exist. [1][2][5]
Why does the label focus so much on sodium?
Desmopressin reduces urine output, and the labels warn that this can lead to water retention and dangerously low sodium. [2][1]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
How to read the evidence labels
Labels used on this page: approved medicine (a regulator has approved it for a named use), promising but limited, mixed, and insufficient evidence.
Approved uses in the United States
| Product (as labeled) | Uses named on the label | Evidence label |
|---|---|---|
| DDAVP tablets | Central diabetes insipidus (replacement for the missing antidiuretic hormone) and primary nocturnal enuresis (bedwetting). Not effective for nephrogenic diabetes insipidus. [1] | approved medicine (FDA) |
| DDAVP injection | Central diabetes insipidus; hemophilia A with factor VIII levels above 5%; mild to moderate von Willebrand's disease type I. First US approval 1978. [2] | approved medicine (FDA) |
| Stimate nasal spray | Hemophilia A and von Willebrand's disease type I (same factor VIII limits). [3] | approved medicine (FDA) |
Central diabetes insipidus is not diabetes mellitus. It is a condition in which the body lacks enough antidiuretic hormone, and the label describes desmopressin as a replacement hormone for it. [2]
Night-time urination (nocturia) is also studied. This page did not verify a nocturia-specific desmopressin approval in the US or elsewhere; the labels read do not list it. EU, UK, Canadian and Australian status: not verified.
Major safety information from the labels
- Low blood sodium (hyponatremia). The injection label carries a boxed warning: severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest or death. [2] The tablet label says unless it is properly diagnosed and treated, hyponatremia can be fatal, so fluid restriction is recommended. [1]
- Who it is not for. The tablet label lists moderate to severe kidney impairment (creatinine clearance below 50 mL/min) and any history of hyponatremia. [1] The injection label also lists loop diuretics, heart failure and uncontrolled high blood pressure. [2]
- Monitoring. The injection label calls for measuring serum sodium within 7 days and about 1 month after starting, then periodically, and more often in people 65 or older. [2] Whether and how often to test is a decision for the prescriber.
- Medicine interactions. Rare reports of seizures from low sodium followed use with oxybutynin and imipramine. [1] See medication interactions.
- Children. The injection label says to restrict fluid intake to prevent hyponatremia and water intoxication in children. [2]
- Pregnancy. The injection label says decades of published experience have not identified a drug-associated risk of major birth defects, miscarriage or other adverse outcomes. [2]
- Absorption. Oral tablets deliver roughly 5% of the exposure of the intranasal form, one reason the forms are not interchangeable. [1]
References
- FDA label (DailyMed): DDAVP Tablets (desmopressin acetate), Ferring Pharmaceuticals. Read 2026-10-22.
- FDA label (DailyMed): DDAVP Injection (desmopressin acetate), Ferring Pharmaceuticals. Read 2026-10-22.
- FDA label (DailyMed): Stimate (desmopressin acetate) nasal spray, Ferring Pharmaceuticals. Read 2026-10-22.
- [Hahn D, Stewart F, Raman G. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 2025 [PubMed 40728007]](https://pubmed.ncbi.nlm.nih.gov/40728007/). Read 2026-10-22.
- [Desmopressin acetate for nocturia in benign prostatic hyperplasia patients: systematic review and meta-analysis. Low Urin Tract Symptoms 2022 [PubMed 35034423]](https://pubmed.ncbi.nlm.nih.gov/35034423/). Read 2026-10-22.
- [Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: systematic review and meta-analysis. Neurourol Urodyn 2024 [PubMed 37746880]](https://pubmed.ncbi.nlm.nih.gov/37746880/). Read 2026-10-22.